JP2025098167A5 - - Google Patents

Info

Publication number
JP2025098167A5
JP2025098167A5 JP2025051382A JP2025051382A JP2025098167A5 JP 2025098167 A5 JP2025098167 A5 JP 2025098167A5 JP 2025051382 A JP2025051382 A JP 2025051382A JP 2025051382 A JP2025051382 A JP 2025051382A JP 2025098167 A5 JP2025098167 A5 JP 2025098167A5
Authority
JP
Japan
Prior art keywords
amino acid
acid position
fcrn antagonist
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025051382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025098167A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/043533 external-priority patent/WO2021016571A2/en
Application filed filed Critical
Publication of JP2025098167A publication Critical patent/JP2025098167A/ja
Publication of JP2025098167A5 publication Critical patent/JP2025098167A5/ja
Pending legal-status Critical Current

Links

JP2025051382A 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法 Pending JP2025098167A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962878541P 2019-07-25 2019-07-25
US62/878,541 2019-07-25
PCT/US2020/043533 WO2021016571A2 (en) 2019-07-25 2020-07-24 Methods of treating antibody-mediated disorders with fcrn antagonists
JP2022504569A JP2022542884A (ja) 2019-07-25 2020-07-24 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022504569A Division JP2022542884A (ja) 2019-07-25 2020-07-24 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Publications (2)

Publication Number Publication Date
JP2025098167A JP2025098167A (ja) 2025-07-01
JP2025098167A5 true JP2025098167A5 (enExample) 2026-01-08

Family

ID=72087159

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022504569A Pending JP2022542884A (ja) 2019-07-25 2020-07-24 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
JP2025051382A Pending JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022504569A Pending JP2022542884A (ja) 2019-07-25 2020-07-24 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Country Status (13)

Country Link
US (1) US20210024620A1 (enExample)
EP (1) EP4004039A2 (enExample)
JP (2) JP2022542884A (enExample)
KR (1) KR20220038432A (enExample)
CN (1) CN114466663B (enExample)
AU (1) AU2020315925A1 (enExample)
BR (1) BR112022001255A2 (enExample)
CA (1) CA3148764A1 (enExample)
CO (1) CO2022001164A2 (enExample)
IL (1) IL290101A (enExample)
MX (1) MX2022001038A (enExample)
TW (1) TW202120539A (enExample)
WO (1) WO2021016571A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120077065A (zh) 2022-07-27 2025-05-30 阿布林克斯有限公司 与新生儿Fc受体的特定表位结合的多肽
EP4658310A1 (en) 2023-01-30 2025-12-10 Kymab Limited Antibodies
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025041077A1 (en) 2023-08-23 2025-02-27 Sanofi Ctla-4-based lysosomal degraders and uses thereof
TW202535925A (zh) 2023-10-25 2025-09-16 比利時商艾伯霖克斯公司 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025144848A1 (en) * 2023-12-27 2025-07-03 Vetmab Biosciences, Inc. FcRn ANTAGONISTS FOR VETERINARY USE

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
CA2536408A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
JP4652414B2 (ja) * 2004-11-12 2011-03-16 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8163881B2 (en) * 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2012132067A1 (ja) * 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
TWI671315B (zh) 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
AU2014261630B2 (en) * 2013-04-29 2019-05-09 F. Hoffmann-La Roche Ag Human FcRn-binding modified antibodies and methods of use
BR112016025393A2 (pt) * 2014-06-12 2017-12-12 Hoffmann La Roche método para selecionar um anticorpo inteiro, pluralidade de anticorpos, uso de uma ou mais mutações de aminoácidos e anticorpo inteiro variante
HRP20191766T1 (hr) * 2014-11-06 2019-12-27 F. Hoffmann - La Roche Ag Varijante fc regije s modificiranim vezanjem na neonatalni fc receptor (fcrn) i postupci primjene
PT3268391T (pt) * 2015-03-09 2021-08-19 Argenx Bvba Métodos de redução dos níveis séricos de agentes contendo fc utilizando antagonistas de fcrn
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
EP3625251A1 (en) * 2017-05-15 2020-03-25 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
WO2019110823A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
KR20250008975A (ko) * 2018-01-26 2025-01-16 젠자임 코포레이션 FcRn에 대한 증진된 결합 및 연장된 반감기를 갖는 Fc 변이체

Similar Documents

Publication Publication Date Title
JP2025098167A5 (enExample)
JP2024026255A5 (enExample)
JP7116736B2 (ja) 操作されたヘテロ二量体タンパク質
JP6334669B2 (ja) 改善された半減期を有する修飾された抗体
CA2684626C (en) Penta-specific antibodies binding il-8, gro-alpha, gro-beta, gro-gamma and ena-78
JP2012516158A5 (enExample)
JP2019504617A5 (enExample)
RU2011135422A (ru) Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
HRP20171080T1 (hr) Protutijela s modificiranim affinitetom za fcrn koja potiču uklanjanje antigena
TW200840821A (en) Methods of purifying anti A beta antibodies
RU2016139006A (ru) Мультимерные fc-белки
IL276286B2 (en) FC variants with improved binding to FCRN and extended half-life
JP2020520231A5 (enExample)
MX2011001909A (es) Anticuerpos anti-interleucina-13 modificados, composiciones, metodos y usos.
CN103459427B (zh) 针对人IgG抗体的CH1结构域中表位的抗原结合蛋白
JP2025522482A (ja) インターロイキン１３に結合する抗体及び使用方法
JP2022542884A (ja) Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
CN116113642A (zh) 多特异性抗体、包含其的组合物、及其载体和用途
RU2019123112A (ru) Анти-il-5 антитела
JPWO2021016571A5 (enExample)
JPWO2019147973A5 (enExample)
JP2024522237A (ja) ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法
JP2020033382A (ja) 抗体の抗原に対する親和性を制御する方法、抗原に対する親和性が改変された抗体及びその製造方法
RU2022104768A (ru) Способы лечения антителоопосредованных нарушений с помощью антагонистов fcrn